JP2021524744A5 - - Google Patents

Info

Publication number
JP2021524744A5
JP2021524744A5 JP2020564841A JP2020564841A JP2021524744A5 JP 2021524744 A5 JP2021524744 A5 JP 2021524744A5 JP 2020564841 A JP2020564841 A JP 2020564841A JP 2020564841 A JP2020564841 A JP 2020564841A JP 2021524744 A5 JP2021524744 A5 JP 2021524744A5
Authority
JP
Japan
Prior art keywords
cancer
gene
carcinoma
adenocarcinoma
gene signature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020564841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033052 external-priority patent/WO2019226514A2/en
Publication of JP2021524744A publication Critical patent/JP2021524744A/ja
Publication of JP2021524744A5 publication Critical patent/JP2021524744A5/ja
Priority to JP2024034926A priority Critical patent/JP2024053048A/ja
Pending legal-status Critical Current

Links

JP2020564841A 2018-05-21 2019-05-20 分子遺伝子シグネチャーとその使用方法 Pending JP2021524744A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024034926A JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862674285P 2018-05-21 2018-05-21
US62/674,285 2018-05-21
US201862747853P 2018-10-19 2018-10-19
US62/747,853 2018-10-19
PCT/US2019/033052 WO2019226514A2 (en) 2018-05-21 2019-05-20 Molecular gene signatures and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024034926A Division JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Publications (2)

Publication Number Publication Date
JP2021524744A JP2021524744A (ja) 2021-09-16
JP2021524744A5 true JP2021524744A5 (https=) 2022-05-30

Family

ID=67002367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564841A Pending JP2021524744A (ja) 2018-05-21 2019-05-20 分子遺伝子シグネチャーとその使用方法
JP2024034926A Pending JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024034926A Pending JP2024053048A (ja) 2018-05-21 2024-03-07 分子遺伝子シグネチャーとその使用方法

Country Status (7)

Country Link
US (1) US20210363590A1 (https=)
EP (1) EP3797173A2 (https=)
JP (2) JP2021524744A (https=)
CN (1) CN112771177A (https=)
AU (1) AU2019275404A1 (https=)
CA (1) CA3100200A1 (https=)
WO (1) WO2019226514A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113631908A (zh) * 2018-12-21 2021-11-09 纳米线科技公司 用于病理试样的移动数字空间剖析的方法、装置、系统和设备
CN115398011A (zh) * 2020-01-31 2022-11-25 亚拉勒提治疗欧洲私人有限公司 用于预测癌症患者的伊沙匹隆反应性的方法
ES2849965B2 (es) * 2020-02-21 2023-11-17 Fundacion Para La Investig E Innovacion Biosanitaria De Asturias Finba Ispa Metodo para predecir o pronosticar la respuesta al tratamiento del cancer
WO2021228888A1 (en) * 2020-05-12 2021-11-18 Asylia Diagnostics Biomarkers for hyperprogressive disease and therapy response after immunotherapy
US20230250173A1 (en) * 2020-07-01 2023-08-10 Pfizer Inc. Biomarkers for pd-1 axis binding antagonist therapy
WO2022012420A1 (zh) * 2020-07-17 2022-01-20 信达生物制药(苏州)有限公司 一种核苷酸组合及其应用
US12263233B2 (en) * 2020-10-19 2025-04-01 Washington University Compositions and methods for modulating Myc target protein 1
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
JP2024508856A (ja) * 2021-03-01 2024-02-28 ジェネンテック， インコーポレイテッド 卵巣がんの診断方法及び処置方法
WO2022211620A1 (en) * 2021-04-01 2022-10-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Cd4/il-2 biomarker.
CN114231623B (zh) * 2021-10-14 2023-09-08 福建中医药大学 Palmdelphin在制备人结直肠癌检测及治疗产品中的应用
US20250002918A1 (en) * 2021-10-22 2025-01-02 The Wistar Institute Of Anatomy And Biology Compositions and methods for treatment of mic60 depleted cancers and metastasis
CN113913507A (zh) * 2021-10-29 2022-01-11 温州医科大学附属第一医院 Ccl3蛋白作为评估非酒精性脂肪性肝病炎症水平及疾病进展的生物标志物的应用
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
US20230257825A1 (en) * 2022-02-04 2023-08-17 City Of Hope Breast cancer biomarkers and methods of use
WO2023155021A1 (en) * 2022-02-18 2023-08-24 London Health Sciences Centre Research Inc. Immune classification tool for determining survival outcomes in cancer
CN115896290B (zh) * 2022-11-29 2023-11-24 中国人民解放军海军军医大学 Trim21基因检测在肿瘤诊断、治疗选择和预后评估中的应用
WO2024227553A1 (en) * 2023-05-01 2024-11-07 The Chancellor, Masters And Scholars Of The University Of Oxford Biomarkers for use in cancer treatment and predicting responsiveness to a cancer therapy
WO2024234348A1 (en) * 2023-05-17 2024-11-21 Yanjun Wang Biomarker for immune checkpoint blockade therapy in nsclc
CN119685476A (zh) * 2024-05-29 2025-03-25 深圳湾实验室 一种与癌症预后相关的基因标志物及其应用
CN119799905B (zh) * 2025-03-14 2025-06-17 浙江省肿瘤医院 乳头状甲状腺癌早期预测标志物、用途及其筛选方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BR9814116A (pt) 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
US7473767B2 (en) 2001-07-03 2009-01-06 The Institute For Systems Biology Methods for detection and quantification of analytes in complex mixtures
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
CN1852974A (zh) * 2003-06-09 2006-10-25 密歇根大学董事会 用于治疗和诊断癌症的组合物和方法
WO2005071419A2 (en) * 2004-01-16 2005-08-04 Ipsogen Protein expression profiling and breast cancer prognosis
EP1930414B1 (en) * 2005-09-08 2012-07-18 Medinet Co., Ltd. Method for activation treatment of antigen-presenting cell
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ，インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
WO2007076128A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
CA2653095C (en) 2006-05-22 2013-07-16 Nanostring Technologies, Inc. Systems and methods for analyzing nanoreporters
US20090076734A1 (en) * 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
EP2808402A3 (en) * 2008-12-29 2015-03-25 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment
WO2011047087A2 (en) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Protein detection via nanoreporters
WO2012129488A2 (en) * 2011-03-23 2012-09-27 Virginia Commonwealth University Gene signatures associated with rejection or recurrence of cancer
GB201217892D0 (en) 2012-10-05 2012-11-21 Virttu Biolog Ltd Treatment of cancer
SG11201502778TA (en) * 2012-10-12 2015-05-28 Agency Science Tech & Res Method of prognosis and stratification of ovarian cancer
AU2014278152A1 (en) 2013-06-14 2015-12-24 Nanostring Technologies, Inc. Multiplexable tag-based reporter system
EP3194440A1 (en) * 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
WO2016049276A1 (en) * 2014-09-25 2016-03-31 Moffitt Genetics Corporation Prognostic tumor biomarkers
US11377693B2 (en) * 2014-12-09 2022-07-05 Merck Sharp & Dohme Llc System and methods for deriving gene signature biomarkers of response to PD-1 antagonists
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック， インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
ES2835866T5 (es) * 2015-05-12 2024-12-02 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
SG10202107053QA (en) 2015-07-17 2021-08-30 Nanostring Technologies Inc Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue
WO2017096458A1 (en) * 2015-12-07 2017-06-15 Ontario Institute For Cancer Research (Oicr) Immune gene signature predictive of anthracycline benefit
WO2017216559A1 (en) * 2016-06-14 2017-12-21 Almac Diagnostics Limited Predicting responsiveness to therapy in prostate cancer
AU2017343779A1 (en) * 2016-10-13 2019-04-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to CTLA4 blockade in melanoma using a gene expression signature
EP3622092A4 (en) * 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
WO2019200223A1 (en) * 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2021524744A5 (https=)
Tu et al. Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
Topalian et al. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy
Mak et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition
Guibert et al. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma
Della Corte et al. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
Sideras et al. PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
Sato et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Mino-Kenudson Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Misale et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
Giovannetti et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non–small cell lung cancer patients treated with gefitinib
Li et al. DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer
La Salvia et al. HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
JP2016534157A5 (https=)
Mandal et al. Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions
Greil et al. Reactivation of dormant anti-tumor immunity–a clinical perspective of therapeutic immune checkpoint modulation
Lin et al. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond
Sung et al. A Polymorphic− 844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer
Kwon et al. Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
JP2019500870A5 (https=)
Hong et al. Angiogenesis-related microRNAs in colon cancer
Wu et al. TOPK promotes the growth of esophageal cancer in vitro and in vivo by enhancing YB1/eEF1A1 signal pathway
Yao et al. Pan-cancer biomarkers: changing the landscape of molecular testing
Necchi et al. Association of androgen receptor expression on tumor cells and PD-L1 expression in muscle-invasive and metastatic urothelial carcinoma: insights for clinical research
Lingohr et al. Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas